Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.9
23.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Arcturus Therapeutics Holdings Inc
Pre-Tax Income
Arcturus Therapeutics Holdings Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
Pre-Tax Income
-$66.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$1.7B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$9.9B
|
CAGR 3-Years
30%
|
CAGR 5-Years
41%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$8.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
16%
|
|
Arcturus Therapeutics Holdings Inc
Glance View
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. The company is headquartered in San Diego, California and currently employs 177 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The firm's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).
See Also
What is Arcturus Therapeutics Holdings Inc's Pre-Tax Income?
Pre-Tax Income
-66.7m
USD
Based on the financial report for Sep 30, 2025, Arcturus Therapeutics Holdings Inc's Pre-Tax Income amounts to -66.7m USD.
What is Arcturus Therapeutics Holdings Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-12%
Over the last year, the Pre-Tax Income growth was -7%. The average annual Pre-Tax Income growth rates for Arcturus Therapeutics Holdings Inc have been 23% over the past three years , -5% over the past five years , and -12% over the past ten years .